Genomics of Common Disease staff

Advancing the genetics and epigenetics of complex human disease

What we do

Our main research aim is to support and advance scientific understanding of the heritable molecular mechanisms and environmental factors that control human susceptibility to complex common diseases, in particular Type 2 Diabetes, obesity and linked illnesses, including cancer.

The methods we use range from innovative big data “omics” analysis to testing specific gene variants in vitro and in vivo. Our results will lay the foundation for precision and personalised medicine, leading to improved medical treatment for patients and targeted lifestyle or pharmaceutical preventative strategies for high-risk individuals

Areas

Students on Human Molecular Genetics course at Hammersmith Campus

Study

We run a yearly 12-month MSc in Human Molecular Genetics which includes a 6-month hands-on research project. This MSc provides practical training in human molecular genetics, gemonics and precision medicine, using advanced molecular and bioinformatic techniques.

In addition we run an annual short course providing an introduction to the statistical analysis or genome-wide association.

Imperial College staff conduction research in the lab

Lead researchers

Professor Philippe Froguel
Identification of genetic and epigenetic risk factors of diabetes, obesity and complications.

Dr Inga Prokopenko
Development of analytical approaches for multi-omics data; large-scale genetic studies for cardiometabolic traits.

Dr Toby Andrew
Gene mapping and functional characterisation of disease susceptibility genes (type 2 diabetes and obesity).

Imperial staff working in the Genotyping facility

Genotyping Facility

The School of Public Health Genotyping Facility is linked to the NIHR Imperial BRC Institute for Translational Medicine and Therapeutics (ITMAT) and provides cutting-edge genotyping capability to internal and external clients.

Our capabilities range from low-throughput single sample SNPs to high throughput Illumina and Fluidigm assays. It also offers state of art Next Generation Sequencing.